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Background
The importance of vascular access for improving clinical care and outcomes in haemodialysis patients is the focus of many quality initiatives around the world (e.g. NKF-KDOQI guidelines 1 , KHA-CARI guidelines 2 , Canadian Society of Nephrology 3 , Fistula First Breakthrough Initiative 4 ). The benefits of a native arteriovenous fistula (AVF) compared with synthetic arteriovenous grafts (AVG) or central venous catheters (CVC) include lower rates of thrombosis, infection, interventions to maintain patency and overall mortality [5] [6] [7] . However, native AVF are more difficult to establish and take longer to mature, resulting in a greater need to maintain CVC and a higher primary access failure rate (ranging between 20-60%). Early and late failure has been attributed to early thrombosis and a failure of maturation 8, 9 .
Vascular access dysfunction is associated with significant morbidity and mortality and is a major economic burden for health care providers and therefore an important target for therapeutic interventions [10] [11] [12] .
Although the short-term post-operative use of anti-platelet agents may reduce early thrombosis rates 8, [13] [14] [15] [16] [17] , no intervention has been shown to significantly improve the proportion of fistulae that achieve the requirement for sustained regular dialysis, defined as the "usability" of AVF. Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) derived from fish and fish oils not only inhibit platelet aggregation but are anti-inflammatory, anti-proliferative and promote vasodilatation all of which may have a favourable impact on the usability of a de novo AVF 18 .
The omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease
(FAVOURED) trial investigated whether omega-3 polyunsaturated fatty acids either alone or in combination with aspirin will effectively reduce primary access failure of de novo AVF in patients with stage 4 or 5 chronic kidney disease and, by doing so, increase the proportion that achieve usability.
In this paper, the baseline characteristics of the FAVOURED trial patients recruited in Malaysia, the United Kingdom (UK), Australia and New Zealand (ANZ) are described. Characteristics of participants recruited before and after introduction of study protocol amendments designed to increase recruitment of a broader and more representative dialysis patient group, including recruitment of patients already receiving aspirin, are compared to evaluate the success of the protocol amendments. The Malaysian participants are compared and contrasted with the combined ANZ and UK cohort.
Methods
Participants
The trial included patients with stage 4 or 5 chronic kidney disease aged over 19 years and currently receiving, or planned within 12 months to receive haemodialysis. Participants underwent AVF surgery in the upper or lower arm as their primary haemodialysis access. Patients were excluded if they received a revision of an existing AVF rather than a de novo AVF, had an increased bleeding risk (bleeding disorder, recent or active GI ulcer, platelet count < 100×10 9 /L, hepatic insufficiency or anticoagulation therapy), were taking non-steroidal anti-inflammatory drugs, anticoagulants or anti-platelet agents with the exception of low-dose aspirin (eligible for the expanded protocol using open-label aspirin), had contra-indications for taking the study agents (planned surgery that would require cessation of the study medication, treatment-resistant syndrome of asthma, rhinitis and nasal polyps or a known allergy to the study agents), or were female patients who were breastfeeding, pregnant or intended to fall pregnant during the study period. Local ethics committees approved the study and all enrolled patients provided written informed consent.
Study design
FAVOURED is an international double-blind, randomised placebo-controlled trial (RCT) conducted in 34 haemodialysis centres of ANZ, the UK and Malaysia. This trial is designed to assess the effect of omega-3 PUFAs (Omacor capsules, 2g twice daily, Abbott, UK) and/or aspirin (100mg daily, Bayer
Healthcare, United States) on 'AVF access failure', defined as a composite of thrombosis, AVF abandonment or cannulation failure at 12 months following de novo AVF creation. The original protocol was a 2x2 factorial-design trial, whereby participants were randomised to one of four treatment groups formed by aspirin or matching placebo and omega-3 fatty acids or matching placebo. implemented in response to the high prevalence of aspirin use and screen failure with selection of a relatively younger and healthier patient cohort. Including patients taking aspirin was expected to enrol a more representative cohort of older patients with a higher prevalence of cardiovascular disease and diabetes. A full discussion of the changes to the study protocol are described in detail elsewhere 19 .
Statistical analysis
Results are expressed as mean ± standard deviation (SD) or median with interquartile range (IQR) depending on distribution characteristics for continuous variables and number (percentage) for categorical variables. Comparisons for continuous data were performed using independent-samples ttests and Wilcoxon rank sum tests, as appropriate. Comparisons for binary measures were performed using Pearson's chi-square tests. Baseline characteristics independently associated with AVF site (upper versus lower arm) were determined using multivariable logistic regression. A p-value less than 0.05 was considered statistically significant. The calculations were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Patient Enrolment
The 
1) Baseline characteristics of all participants
Baseline characteristics of all 568 participants are shown in Table 1 . Participants were predominantly male and Caucasian or Asian. The proportion of Indigenous participants was similar to that of the general incident haemodialysis population of Australia and New Zealand 20 . Their mean age was 54.8 ± 14.3 years. Most were overweight or obese; almost half had diabetes mellitus and half were former or current smokers, although only a minority had ischaemic heart disease (IHD, 8%) or congestive heart disease (4%). The majority of trial participants had systolic hypertension. The most common causes of chronic kidney disease were diabetic nephropathy (39%), hypertensive nephropathy (14%) and glomerulonephritis (14%). Half of the participants were not receiving renal replacement therapy and had no other dialysis access at the time of AVF creation, which was predominantly planned for the lower arm. Forty two percent of participants were receiving haemodialysis via a CVC at the time of AVF creation. The mean haemoglobin was 108 ± 19g/L. Platelet counts and coagulation profiles were normal in the vast majority of participants.
2) Comparison of Australian and New Zealand participants pre-and post-amendment of the study protocol
Following protocol modifications to allow for open-label aspirin use in patients committed to aspirin, an additional 219 ANZ participants were enrolled and compared with the 184 participants from the original protocol (Table 2 ). The average age of the ANZ cohort increased from 54.6 years to 56.9
years. The proportion of Indigenous participants increased (from 13 to 19 %) and that of Caucasians decreased (from 74% to 71%, p=0.07). Diabetes mellitus was present in 43% of post-modification participants compared with the original 33% (p=0.03), IHD and congestive heart disease increased to 14% and 7%, respectively, compared with 4% (p<0.001) and 1% (p<0.01), respectively. The mean body mass index (BMI) and waist-to-hip ratio (WHR) but not blood pressure were significantly higher following protocol amendments and diabetic nephropathy as a cause of end-stage kidney disease (ESKD) was more prevalent post-protocol modification (37% versus 22%).
There was an increase in planned creation of lower arm AVF (72% compared with 59%, p<0.01) but no significant variation in renal replacement modality or type of dialysis access prior to AVF creation compared with the pre-modification trial cohort. Whilst the average fasting glucose level and HbA1C were significantly higher in the post-modification cohort (6.8mmol/L and 6.6% compared to 6.1mmol/L and 6%, respectively, p<0.05), total cholesterol and LDL-cholesterol levels were reduced.
3) Comparison of combined ANZ and UK participants with Malaysian participants postprotocol amendment
Baseline data comparing the Malaysian cohort (n=156) with the combined ANZ (n=219) and UK (n=9) participants (ANZUK n=228) recruited after protocol modifications are presented in Table 3 .
Malaysian participants were significantly younger, shorter and had a lower BMI, but had a similar WHR when compared with the ANZUK group.
Although diabetes mellitus was significantly more prevalent in the Malaysian cohort (65% versus 43%, p < 0.001), IHD (5% versus 14%) and smoking (current or former = 40% versus 58%) were less common than in the ANZUK cohort (both p < 0.01). At the time of enrolment, Malaysian participants had a significantly lower rate of aspirin use (32%) than ANZUK participants (49%, p=0.001).
A lower arm AVF was planned in 48% of Malaysian participants compared to 71% in the combined group. Multivariable regression analysis adjusted for relevant potential confounders indicate that the likelihood of undergoing lower arm AVF surgery was strongly associated with male gender, younger age, and country (ANZUK), but not BMI or diabetes status (Table 4) 
4) Comparison between FAVOURED and two recent anti-platelet trials of vascular access outcomes
To date, there has only been one large RCT evaluating the impact of fish oil supplementation on access survival, which was performed in North America and Canada (FISH study) 21 . This study was conducted in participants receiving a de novo arterio-venous graft as opposed to a native arterio-venous fistula 21 . With regards to native AVF, access failure has so far only been evaluated with short-term (6 weeks) post-operative use of clopidogrel or placebo in a large North American RCT 8 . Patient baseline characteristics of the FAVOURED study, although generally similar to these two North American/Canadian studies, did have some important differences ( Table 5 ). The average age and male predominance was similar in the FAVOURED and the clopidogrel trial, but the average age was higher and gender distribution equal in the FISH study. The prevalence of diabetes mellitus was highest in participants undergoing AVG surgery (53%) compared to participants receiving an AVF (46% and 48% in the FAVOURED and clopidogrel trial, respectively). The rate of IHD was considerably higher in the North American/Canadian studies (34-48%) compared to that of the FAVOURED trial (8%).
Discussion
FAVOURED is the first RCT designed to determine whether the use of omega-3 fatty acids with or without aspirin will improve the usability of de novo AVF. Patients enrolled in FAVOURED were overweight with a male predominance, a high prevalence of diabetes mellitus and current or past smoking history. However, trial participants were on average younger and had lower rates of IHD and congestive heart failure compared with the general haemodialysis population and comparable study cohorts 8, [21] [22] [23] [24] . The trial design was modified in response to concerns about slow recruitment due to widespread prevalent aspirin use in order to facilitate recruitment and improve generalizability.
Examination of the baseline data confirms that the modified trial protocol was consistent with the intended aims to recruit a more representative trial population by including a broader demographic with participants from Malaysia, Australia, New Zealand and the UK.
The original study protocol had excluded patients that were unable to cease aspirin, which resulted in an unexpectedly high screening failure rate and slow recruitment of a relatively young and healthy study cohort. Following protocol amendments to allow for open-label aspirin use, screening failure rates due to treatment with anticoagulants and antiplatelet agents decreased from 41% to 10%, the proportion of diabetic patients increased by almost one third, the prevalence of IHD more than 3-fold and that of congestive heart disease by almost six times. This is consistent with international data on patients from ANZ, Europe, Japan and North America showing that diabetes mellitus and IHD were significantly more prevalent in patients taking aspirin compared with those not taking aspirin 25 . Postprotocol amendment, diabetes prevalence in this study (43%) was similar to that reported in incident haemodialysis patients in Australia (47%) and New Zealand (53%) 22, 26 . In contrast, the prevalence of IHD in the trial cohort remained considerably lower (14%) than that reported in incident ANZ haemodialysis populations (on average 24-32%) 22, 26 . This may in part reflect physicians' concern or patient preference regarding the risk and benefit of participating in FAVOURED based upon their baseline cardiovascular risk.
Patients recruited from Malaysia represent one third of the final trial population and had significant baseline differences compared with participants from the combined ANZ and UK cohort. Malaysians, whilst on average younger and slimmer, had a greater prevalence of diabetes and diabetic nephropathy Whilst the average age and male preponderance of FAVOURED participants was comparable to that of the clopidogrel trial 8 , the cohort of the FISH study 21 was older with an equal proportion of female participants. This may be explained by differences in patient selection for an AVF as opposed to an AVG and regional differences in practice patterns. Older patients with smaller vessels may still be suitable for an AVG but not for a native AVF. Whilst the proportions of patients with diabetes mellitus were comparable across the three studies, the rates of ischaemic and congestive heart disease were considerably lower in the FAVOURED cohort suggesting differences in patient selection. In North 
Limitations
Comparison of baseline characteristics between the study population and registry data was limited by differences in data collection. Whilst ANZDATA collects information on incident and prevalent haemodialysis patients separately, Malaysia focuses mainly on characteristics of incident haemodialysis patients and the US registry reports on the entire population with chronic kidney disease and those with ESKD, respectively.
Conclusion
The FAVOURED study successfully enrolled a large number of participants undergoing de novo AVF creation with baseline characteristics that, for the most part, were similar to contemporary registry 
